Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intetumumab +/- Dacarbazine in Stage IV Melanoma
NCT00246012Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2005
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of intetumumab in melanoma (9 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Maximum Observed Serum Concentration of Intetumumab and 1 more. Started May 2005; status: completed.
02
Drugs
intetumumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00246012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246012.